Cell Therapy for Glioblastoma Multiforme is under clinical development by ZhongSheng BioTech and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cell Therapy for Glioblastoma Multiforme’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cell Therapy for Glioblastoma Multiforme overview

Cellular immunotherapy is under development for the treatment of glioblastoma multiforme. The therapeutic candidate comprises autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides.

ZhongSheng BioTech overview

ZhongSheng BioTech is a tech pharmaceutical company provide marketing and manufacturing in the area of food additives. The company is headquartered in China.

For a complete picture of Cell Therapy for Glioblastoma Multiforme’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.